{
    "nctId": "NCT01478477",
    "briefTitle": "Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole",
    "officialTitle": "Prevention of Aromatase Inhibitor-Induced Joint Symptoms With Omega 3 Fatty Acid Supplementation: a Randomized Placebo Controlled Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "Pain score change after 6 months (6 months -baseline) based on the FACT-B/ES instrument",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women diagnosed with breast cancer stages I-III initiating first adjuvant AI therapy with any of the Food and Drug Administration- (FDA) approved AIs (anastrozole, exemestane, letrozole)\n* Concurrent gonadotropin-releasing hormone (GnRH) agonist therapy is allowed\n* Concurrent breast related radiation therapy is allowed\n* Prior tamoxifen use is allowed\n* Prior chemotherapy is allowed\n* History of osteoarthritis and/or fibromyalgia is allowed\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Metastatic malignancy of any kind\n* Rheumatoid arthritis and other types of autoimmune and inflammatory joint disease, with the exception of osteoarthritis and fibromyalgia\n* AI use \\> 2 weeks prior to study enrollment\n* Known bleeding disorders\n* History of diabetes mellitus, heart disease or TIA/stroke\n* Current use of warfarin or other anticoagulants\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,or psychiatric illness/social situation that would limit compliance with study requirements\n* Daily use of n-3 PUFA concentrates or capsules or regular or any other supplements that might interact with n-3 PUFA supplements within six months of study initiation; sporadic use of n-3 PUFA supplement may be eligible if there has been a 3-month washout period prior to randomization\n* Pregnant or nursing women\n* Known sensitivity or allergy to fish or fish oil\n* Concurrent use of daily full dose aspirin (\u2265 325 mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs) or NSAID-containing products or steroids; one month washout period is required prior to randomization\n* Unable to give informed consent\n* In patients consenting for optional MRIs, any contraindication to MRI examination including but not limited to ferromagnetic metal in the body, pacemaker, or severe claustrophobia",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}